FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE GIRONA DOCTOR JOSEP TRUETA

Their core work

IDIBGI is a biomedical research institute in Girona, Spain, focused on translational clinical research — turning lab discoveries into patient-relevant treatments and decision-support tools. Their core work spans metabolic diseases (obesity, PCOS), neurological conditions (stroke recovery, cognitive aging), and cancer diagnostics (prostate cancer imaging). They contribute clinical expertise, patient cohort access, and biomedical data analysis to large European consortia tackling complex chronic diseases.

What they specialise in

How they've shifted over time

In their early H2020 participation (2015–2016), IDIBGI focused on regenerative medicine and stroke recovery through stem cell therapy (RESSTORE) and on predictive clinical decision tools for chronic disease (PEPPER). From 2020 onward, their work shifted markedly toward metabolic conditions — obesity phenotyping, PCOS, gut-brain interactions — and toward data-intensive approaches including AI imaging platforms and federated health databases. The trajectory shows a clear move from interventional cell therapies to data-driven precision medicine for metabolic and aging-related diseases.

IDIBGI is moving toward data-driven, algorithm-based approaches to obesity, aging, and hormonal disorders — expect future work combining clinical cohorts with AI analytics and microbiome data.

How they like to work

IDIBGI operates exclusively as a consortium participant, never as coordinator, which is typical of a clinically oriented research institute contributing domain expertise and patient data to larger collaborative efforts. With 119 unique partners across 24 countries in just 6 projects, they join large-scale consortia (averaging ~20 partners per project). This makes them an accessible, experienced partner comfortable working within complex multinational teams without seeking a leadership overhead role.

Despite only 6 projects, IDIBGI has built a remarkably broad network of 119 partners spanning 24 countries, reflecting their participation in large pan-European health consortia. Their reach covers most of the EU with no narrow geographic clustering.

What sets them apart

IDIBGI sits at the intersection of clinical metabolic research and emerging digital health tools — a combination not common among Spanish biomedical institutes of their size. Their simultaneous involvement in obesity phenotyping, gut-brain research, and AI-assisted cancer imaging gives them a rare cross-disciplinary clinical perspective. For consortium builders, they offer a reliable specialist partner with direct access to patient populations in a Mediterranean health system and proven ability to work across very different medical domains.

Highlights from their portfolio

• SOPHIA
  Largest single grant (EUR 300,000 in a project running to 2026), tackling obesity stratification with federated databases and treatment algorithms — their most strategically central project.
• SmartAge
  Their highest-funded project (EUR 501,810) under MSCA-ITN, investigating the gut-brain axis and cognitive aging — represents their strongest investment in microbiome research.
• ProCAncer-I
  A departure from their metabolic focus into AI-powered prostate cancer imaging, signaling expansion into digital health and cloud-based medical AI platforms.